We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

267 hedge funds and large institutions have $7.29B invested in Neurocrine Biosciences in 2017 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 82 increasing their positions, 93 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

210% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 21

24% more capital invested

Capital invested by funds: $5.88B → $7.29B (+$1.41B)

20% more funds holding

Funds holding: 223 → 267 (+44)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

2.62% less ownership

Funds ownership: 108.79% → 106.18% (-2.6%)

12% less repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 93

22% less call options, than puts

Call options by funds: $30.8M | Put options by funds: $39.6M

Holders
267
Holders Change
+44
Holders Change %
+19.73%
% of All Funds
6.06%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
65
Increased
82
Reduced
93
Closed
21
Calls
$30.8M
Puts
$39.6M
Net Calls
-$8.73M
Net Calls Change
-$22.8M

Top Buyers

1
Artisan Partners
Artisan Partners
Wisconsin
+$66.1M
2
American Century Companies
American Century Companies
Missouri
+$31M
3
Millennium Management
Millennium Management
New York
+$28.5M
4
BBA
Baker Bros. Advisors
New York
+$26.5M
5
Renaissance Technologies
Renaissance Technologies
New York
+$26.4M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$66.6M
2
HM
HealthCor Management
New York
-$38.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$37.3M
4
Deutsche Bank
Deutsche Bank
Germany
-$32.8M
5
State Street
State Street
Massachusetts
-$32M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$59.2M +$842K +12,347 +2%
Macquarie Group
27
Macquarie Group
Australia
$55.1M -$3.64M -53,311 -7%
Capital World Investors
28
Capital World Investors
California
$53.4M – – –
Bank of America
29
Bank of America
North Carolina
$45.8M +$2.84M +41,664 +8%
MWNA
30
Marshall Wace North America
New York
$43M -$10.9M -160,280 -22%
JP Morgan Chase
31
JP Morgan Chase
New York
$42.1M +$841K +12,331 +2%
Citadel Advisors
32
Citadel Advisors
Florida
$41.7M +$21.9M +320,800 +148%
Millennium Management
33
Millennium Management
New York
$41.5M +$28.5M +417,661 +357%
American Century Companies
34
American Century Companies
Missouri
$38.1M +$31M +454,500 +1,257%
RSCM
35
Rock Springs Capital Management
Maryland
$37.7M +$3.14M +46,000 +10%
Neuberger Berman Group
36
Neuberger Berman Group
New York
$37M +$1.47M +21,500 +5%
Northern Trust
37
Northern Trust
Illinois
$36.3M +$510K +7,475 +2%
UBS AM
38
UBS AM
Illinois
$36.1M -$3.72M -54,520 -10%
Charles Schwab
39
Charles Schwab
California
$31.8M +$1.76M +25,834 +7%
GPP
40
Great Point Partners
Connecticut
$31M -$5.12M -75,000 -16%
Renaissance Technologies
41
Renaissance Technologies
New York
$30M +$26.4M +387,241 New
Balyasny Asset Management
42
Balyasny Asset Management
Illinois
$28.1M -$16.4M -240,633 -40%
TCIM
43
TIAA CREF Investment Management
New York
$27.3M +$3.05M +44,642 +15%
Allianz Asset Management
44
Allianz Asset Management
Germany
$27.2M +$21.2M +310,214 +773%
CS
45
Credit Suisse
Switzerland
$25.3M +$6.09M +89,320 +38%
Jennison Associates
46
Jennison Associates
New York
$25.3M +$292K +4,278 +1%
TCM
47
Tekla Capital Management
Massachusetts
$25.2M -$16.2M -237,400 -42%
CCI
48
Columbus Circle Investors
$24.7M +$21.7M +318,806 New
NIPH
49
NN Investment Partners Holdings
Netherlands
$23.4M +$2.19M +32,158 +12%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$22.8M +$2.3M +33,688 +13%
1
2
3 4 5

NBIX Hedge Fund Activity: Q4 2017 in Review

267 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2017, worth a combined $7.29B — up 24% from $5.88B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new NBIX positions and 21 closed out — a net gain of 44 holders — while 82 added to existing stakes and 93 trimmed.

The largest buyer was Artisan Partners, adding an estimated $66.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $66.6M.

  • 267 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2017, up from 223 in Q3 2017.
  • Funds reported $7.29B of Neurocrine Biosciences stock for Q4 2017, up 24% quarter-over-quarter.
  • 65 funds opened new Neurocrine Biosciences positions in Q4 2017 and 21 closed out, a net change of +44 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2017 was Artisan Partners, an estimated $66.1M added.
  • The largest Neurocrine Biosciences seller in Q4 2017 was T. Rowe Price Associates, an estimated $66.6M sold.

Based on aggregated 13F filings for Q4 2017.